Spotlight
Clinical
Conferences
CME/CE
Relapsed/Refractory HER2+ Metastatic Breast Cancer
Recommendations for managing 2 patient cases specific to HER2-positive metastatic breast cancer and optimizing therapy for specific patient populations within the HER2-positive space based on emerging treatments and changes to standards of care.
EP. 6: Cancer Network Around the Practice: Relapsed/Refractory HER2+ Metastatic Breast Cancer
April 23rd 2021This article reviews the recent development of HER2-targeted therapies with central nervous system (CNS) activity that may improve survival of patients with CNS metastases and prevent development of new CNS metastases. This article also features insights from oncology experts Adam M. Brufsky, MD, PhD; V. K. Gadi, MD, PhD; Sara A. Hurvitz, MD; and Neil M. Iyengar, MD.
